+

WO2009006921A1 - Substance microporeuse pour implant chirurgical - Google Patents

Substance microporeuse pour implant chirurgical Download PDF

Info

Publication number
WO2009006921A1
WO2009006921A1 PCT/EP2007/006093 EP2007006093W WO2009006921A1 WO 2009006921 A1 WO2009006921 A1 WO 2009006921A1 EP 2007006093 W EP2007006093 W EP 2007006093W WO 2009006921 A1 WO2009006921 A1 WO 2009006921A1
Authority
WO
WIPO (PCT)
Prior art keywords
microporous material
surgical implant
implant according
carvacrol
matrix
Prior art date
Application number
PCT/EP2007/006093
Other languages
English (en)
Inventor
Barrera Jose Bouza
Original Assignee
Barrera Jose Bouza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barrera Jose Bouza filed Critical Barrera Jose Bouza
Priority to PCT/EP2007/006093 priority Critical patent/WO2009006921A1/fr
Publication of WO2009006921A1 publication Critical patent/WO2009006921A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges

Definitions

  • the present invention relates to a microporous material for surgical implant, which contains inorganic substances found in bone structures, particularly calcium phosphate, mineral salts and plant components.
  • the invention also relates to a procedure for producing said implants and to the uses thereof.
  • the materials used until now have been elements with a negative charge known as electrets, which do not contribute to the short-term neoformation of the surrounding tissue. Furthermore, said materials are not very receptive to tissue liquid exchange, which makes their integration more difficult.
  • surgeon is supplied with materials that are already shaped or adapted for positioning in the required part of the body. These materials cannot be cut or bevelled with scissors or a scalpel to make them fit any kind of surface.
  • Document WO2004/071543 discloses an injectable mixture for the replacement of bone tissue that comprises a bone cement with two components that forms a self-hardening paste; and a third component that is a liquid that cannot be mixed with the cement paste, which can be washed or removed once the injectable mixture has hardened.
  • This mixture also comprises an organic x-ray contrast agent.
  • Paste-like mixtures are therefore used, which can be used to secure implants as in document US 4093576, consisting of mixtures that comprise a non-water-soluble composition made from polymethacrylate and a cellulose ether.
  • these pastes are not a substitute for ceramic or metal implants that must be positioned in the required areas.
  • This material is irreversible and as it is stronger than the membranes of the surrounding skin or tissue, it often causes fractures or wounds to the person who carries the implant.
  • WO2006/045851 discloses a surgical material that is influential in terms of induction, conduction and osseointegration, which is made from hydrocarbons and celluloses and is highly elastic and stable.
  • the inventors have discovered and developed a new microporous material with which to design surgical implants, which overcomes all the aforementioned drawbacks.
  • the proposed materials are biocompatible and they allow tissue vascularisation and osseointegration.
  • a microporous material for surgical implant of the type that comprises inorganic compounds found in bone structures, particularly calcium phosphate and mineral salts found in bone structures, said material being characterised in that it has a cartilaginous consistency in the presence of a composition comprising carvacrol or a carvacrol derivative; and in that it comprises a matrix that supports the inorganic compounds found in said bone structures and that it, in turn, comprises polysaccharides, carvacrol or one of its derivatives and compounds resulting from the esterification reaction of acrylic acid or a derivative thereof with at least one polyalcohol, all the components of the matrix being interconnected.
  • the microporous material for surgical implant according to the invention is characterised in that the carvacrol derivative is a carvacrol ether selected from the group consisting of methylcarvacrol and ethylcarvacrol or a carvacrol ester resulting from esterification with carvacrol of the organic acids methanoic and/or ethanoic acid.
  • the carvacrol derivative is a carvacrol ether selected from the group consisting of methylcarvacrol and ethylcarvacrol or a carvacrol ester resulting from esterification with carvacrol of the organic acids methanoic and/or ethanoic acid.
  • the polysaccharides comprise ethyl cellulose. - A -
  • microporous material for surgical implant according to the invention is also characterised in that the acrylic acid derivative is methyl acrylate.
  • the polyalcohol is chosen from the group consisting of propanetriol, ethanediol and alcohols with at least three hydroxyl groups.
  • the microporous material for surgical implant according to the invention is characterised in that the matrix that supports the inorganic compounds can be produced by mixing compounds resulting from the esterification of polyalcohols and acrylic acid or its derivatives in a percentage of 55% to 60% of the total weight of the matrix; 35% to 40% of ethyl cellulose of the total weight of the matrix; 5% to 10% of cellulose modified by substituting the hydroxyl groups for radicals chosen from the group consisting of car boxy I, linear alkyls with 1 to 6 carbon atoms, and acetate; and 0.5% to 5% of pharmaceutically acceptable excipients in relation to the total weight of the matrix, where said excipients comprise at least carvacrol and/or an ether or ester derivative thereof.
  • the interconnected microporous structure is produced thanks to the nature of the molecules that make up the material, due to both the interconnection of the components of the liquid matrix and the physical interactions established between said liquid matrix and the solid component that it supports.
  • the inorganic compounds that are found in bone structures are taken from marine fossils.
  • marine fossils consisting of coral or coralline derivatives and/or seaweed.
  • the microporous material for surgical implant comprises not only carvacrol or its derivatives, but also other antiseptic substances.
  • the carvacrol comes from Thymus vulgaris extract.
  • microporous material for surgical implant according to the invention is also characterised in that its porosity is greater than or equal to 500 microns.
  • this surgical microporous material it takes the form of blocks, sheets or spheres, which can then be moulded to the place where the implant is to be inserted due their soft cartilaginous consistency.
  • Another object of the present invention is a procedure for producing a microporous material for surgical implant, which is characterised in that it comprises the following steps:
  • a) process by purifying, crushing, grinding and macerating a solid component extracted from marine fossils, which comprises a mixture of compounds that include at least calcium, magnesium, sodium, potassium, phosphates, chlorine and fluoride;
  • step c) mixing the solid component of step a) with the liquid component of step b);
  • step f) heating the implants formed in step f) between 8O 0 C and 12O 0 C to produce a microporosity of more than or equal to 500 microns;
  • step i) packaging the product consisting of the implant and the composition added in step i).
  • the procedure for producing a microporous material according to the invention is characterised in that the liquid matrix from step b) can be produced by mixing compounds resulting from the esterification of polyalcohols and acrylic acid or its derivatives in a percentage of 55% to 60% in relation to the total weight of the matrix; 35% to 40% of ethyl cellulose in relation to the total weight of the matrix; 5% to 10% of cellulose modified by substituting the hydroxyl groups for radicals chosen from the group consisting of carboxyl, linear alkyls with 1 to 6 carbon atoms, and acetate; and 0.5% to 5% of pharmaceutically acceptable excipients in relation to the total weight of the matrix, where said excipients comprise at least carvacrol and/or an ether or ester derivative thereof.
  • the procedure for producing a microporous material according to the invention is characterised in that in step d) the mixture passes through at least three purification phases in which it comprises 60% by weight of functional hydroxyl groups; 80% by weight of functional hydroxyl groups and 90% by weight of functional hydroxyl groups, respectively.
  • the procedure for producing a microporous material for surgical implant according to the invention is also characterised in that the pH of the mixture produced in step b) and final product before it is packaged are controlled so that the pH is between 4.5 and 6.0.
  • the pH is adjusted to 5.
  • the procedure for producing a material for surgical implant according to the invention includes performing quality controls on the implant material after step h) and after step i), withdrawing any units that do not comply with the pre-established criteria and feeding them back into the procedure by collecting said units in a general collector that supplies the raw materials.
  • Another object of the present invention is a microporous surgical implant that can be produced according to the aforementioned procedure.
  • Another object of the present invention is the use of the microporous material for surgical implant, or an already formed or pre-formed surgical implant as a bone structure or bone tissue substitute.
  • Another object of the present invention is the use of the microporous material for surgical implant, or an already formed or pre-formed surgical implant to fill bone cavities in reconstructive and/or cosmetic surgery.
  • Another object of the invention is the use of the microporous material for surgical implant for ophthalmology in the reconstruction of the supra- and infraorbital ridges, vertical laminas, orbital floor, zygomatic arch and malar bones.
  • Another object of the present invention is the use of the microporous material for surgical implant for stomatological injury surgery.
  • Another object of the present invention is the use of the microporous material for surgical implant for substitution or replacement in trauma injuries with bone loss.
  • Another object of the invention is the use of the microporous material for surgical implant for tumour lesions and lesions caused by osteomyelitis.
  • Fig. 1 shows a patient with a defect in the frontal area of the skull (A), said defect having been corrected after implantation of the microporous material for surgical implant according to the invention (B).
  • Fig. 2 shows another intervention performed on a patient who required the implantation of a large area of material to re-establish another defect in the frontal and parietal part of the skull:
  • Fig. 2A shows a moment during the surgical intervention after the implantation of a large plaque of microporous material with a very well-defined concavity that is suitable to cover a relatively large area of the skull.
  • Fig. 2B shows the result of the operation once the material has been implanted.
  • Fig. 3 shows another example of application of the microporous material of the invention, in this case for maxillofacial reconstruction.
  • the object of the present invention is a material that can be used as a surgical implant, identified in the figures by reference no. 1 , which can be supplied in the finished form and which imitates the endogenous structure that it substitutes, or it can be pre-formed, being applicable in both forms as a substitute for bone structure or bone tissue.
  • the material 1 that is the object of the invention is a microporous material with a composition made from components found in bone structures, particularly calcium phosphate and mineral salts, whose main characteristic is that it has a cartilaginous consistency in the presence of a composition comprising an ester type compound. This cartilaginous consistency allows the surgeon to mould the material to the most suitable shape for the place where it is to be implanted, adapting it to the particularities of each patient.
  • a preferred composition of said microporous material 1 is given below by way of an example.
  • the microporous material 1 comprises a liquid matrix made from polysaccharides, carvacrol or one of its derivatives and compounds resulting from the esterification reaction of acrylic acid or a derivative thereof with at least one polyalcohol.
  • the microporous material 1 also comprises a solid component extracted from marine fossils, which contains salts and other inorganic compounds that are found in bone structures, such as calcium phosphate and associated mineral salts that imitate the conditions or surroundings of the endogenous tissue.
  • excipients used are compounds known by a person skilled in the art, to give the composition antiseptic properties, the desired viscosity, etc.
  • the weight percentages may vary without this detracting from the properties and final consistency of the microporous material 1.
  • the weight percentage of the compounds resulting from condensation of acrylic acid derivatives with polyalcohols is 55% to 60%; the weight percentage of ethyl cellulose is between 35% and 40%; and the weight percentage of modified cellulose is between 5% and 10% of the total weight of the liquid matrix.
  • a suitable amount of excipients between 0.5% and 5% are added to give the composition the desired properties.
  • the ethyl cellulose is produced according to the following sequence or reaction: (C 6 H 10 O 5 )n + XC 2 H 5 OH (C 6 H 10 -XOC 2 H 5 )Ii + XH 2 O
  • excipients are understood to be compounds known by a person skilled in the art, which provide a composition with the desired physical properties.
  • the carvacrol or Thymus vulgaris extract that it comprises is used as an antiseptic and means that the microporous material does not have to be sterilised prior to its use, as it is already in a sterile environment.
  • all these elements are in the form of inorganic salts e.g. calcium phosphate or hydroxyapatite.
  • traces of elements such as copper, tin or zinc or the amounts of iron, chloride, etc., are even lower than those normally found in the human body, meaning that they are not harmful.
  • the marine fossils processed to extract these elements or solid component may consist of coralline and seaweed.
  • the solid and liquid components are processed together to achieve a mixture with a cartilaginous consistency in the presence of a composition containing carvacrol or one of its derivatives from Thymus vulgaris extract.
  • the cartilaginous consistency which makes the material malleable, is maintained provided that said material is in contact with this composition with at least one carvacrol derivative or carvacrol itself; i.e. when partially submerged, fully submerged or in contact with the steam from this composition, the material 1 acquires and maintains the property of being cartilaginous.
  • the material 1 is provided with the desired microporosity, which is always equal to or more than 500 microns.
  • This microporosity means that after implantation of the material 1 , the blood vessels can invade it during the natural processes of angiogenesis, making it possible to vascularise the implanted area.
  • This microporosity also promotes cell migration and invasion by the surrounding tissues (generally bone tissue and conjunctive tissue), the implant thus being perfectly integrated into the body.
  • the intrinsic composition of the material itself also facilitates a greater exchange of molecules, cells and fluids in the human organism. Therefore, at least two independent phenomena facilitate the integration of the implant, promoting growth of the tissue in all directions.
  • the microporous material 1 for surgical implant as defined in the above example may be moulded and extended, or cut and spliced to another piece of the same material 1 to form the implant required for each area. Once it is free from the presence of the composition with carvacrol or a carvacrol derivative in which it is supplied, the microporous material 1 hardens gradually until it takes on a consistency and hardness similar to that of the bone, or even harder than the bone. This hardening procedure can be speeded up if a warm saline solution (water and electrolytes) is added to the area when it is implanted, as is commonly done during surgical interventions to imitate the endogenous environment as much as possible.
  • a warm saline solution water and electrolytes
  • the microporous material 1 has a micro-crystalline structure, in the sense that all its components are relatively ordered, slightly opaque, which takes on particular characteristics of the autogenous bone 72 hours after having been inserted and when joined to the live tissue.
  • This microporous material 1 for implants can be supplied with the implant shape already formed, e.g. imitating a molar, an eyeball, etc.; or in the form of blocks or sheets that the surgeon moulds, cuts (with a scalpel or scissors) and adapts to the area where it is to be placed.
  • the material may be supplied in the form of spheres with a 12, 14, 16, 18, 20 and 22 mm diameter. It may also be supplied with the form of the piece that is to be replaced and/or implanted, e.g. concave areas corresponding to parts of the skull, elongated structures with the shape of bone ends, etc.
  • the material 1 can be cut without the pores collapsing, or without the surface cracking or deforming, which enables the surgeon to adapt or personalise the implant.
  • the process begins by purifying, crushing, grinding and macerating the solid component extracted from marine fossils, which comprises a mixture of compounds that include at least calcium, magnesium, sodium, potassium, phosphates, chlorine and fluoride.
  • a liquid matrix or liquid component is produced by mixing polysaccharides, carvacrol or one of its derivatives and compounds resulting from the esterification reaction of acrylic acid or a derivative thereof with at least one polyalcohol, all the components of the matrix being interconnected.
  • the solid component is mixed with the liquid component and they are homogenised to achieve a mixture with an interconnected microporous structure and cartilaginous consistency in the presence of carvacrol or a carvacrol derivative.
  • the matter or mixture is left to stand and is subjected to a purification procedure in a series of consecutive phases in which the mixture increases in terms of the number of functional hydroxyl groups.
  • the mixture thus produced is put under pressure (from 100 to 200 atm) to compact it and then it is extruded to form 7cm x 2cm x 2cm blocks.
  • the blocks thus formed are heated to a temperature of 8O 0 C to 12O 0 C so that the microporosity of the material is equal to or more than 500 microns.
  • a control is then performed to rectify and/or calibrate the outer layer of said blocks, in order to remove rough edges or bumps.
  • the blocks are fully or partially submerged in the composition comprising at least one carvacrol ester or ether type compound, preferably from
  • Thymus vulgaris extract which acts as an aseptic agent, keeping the blocks in sterile conditions; and then the product consisting of the 7cm x 2cm x 2cm blocks and the preservative composition with said ester type compound is packaged.
  • pH controls are performed at different stages of the procedure for producing the microporous material for surgical implant, particularly when the liquid matrix is produced, as it must be kept at between pH 4.5 and 6, but preferably at pH 5.
  • quality and process controls are performed at different strategic points e.g. after the step when the outer layer is removed, rectified and/or calibrated; or after having added the composition comprising at least one carvacrol ester type compound or a carvacrol ether. Faulty units are recycled via a general raw material collector.
  • the addition of antibiotic substances is anticipated, whereby, as well as being manufactured in sterile conditions and kept in a sterile environment thanks to the ester from Thymus vulgaris extract, it is designed to already include substances that are generally administered after a surgical intervention to prevent the wound from becoming infected.
  • the extrusion and/or moulding step it is possible to produce the material 1 with different surface morphologies, whether smooth, granulose, rough, intra-and extra-porous, etc.
  • This material 1 can be subjected to temperatures of -5 0 C to 5O 0 C without it losing its intramolecular properties.
  • the preferred and normal working temperatures range between 2O 0 C and 3O 0 C.
  • a piece of the microporous material 1 for surgical implant was applied to a patient 2 with a deformation in the frontal part 3 of the skull.
  • the piece was previously flat and before being implanted it was pre- formed to give it the curvature and concavity typical of the endogenous bones that constitute this part of the skull.
  • Fig. 1 B shows the successful final result of the reconstruction.
  • FIGS. 2A and 2B show the reconstruction carried out on a patient 2 in whom a large area of the frontal 3 and parietal 4 bones had to be replaced.
  • Fig. 2A and 2B show the reconstruction carried out on a patient 2 in whom a large area of the frontal 3 and parietal 4 bones had to be replaced.
  • FIG. 2B shows an image of the patient's head 2 with the implant already in place and with the skin already sutured. It can be seen that, as well as having been able to replace the original structure, the external appearance of the head corresponds to a normal skull that has not been operated on.
  • Figs 1 (A and B) and 2 (A and B) show that the microporous material 1 consisting of a matrix of polysaccharides, carvacrol or one of its derivatives and compounds resulting from the esterification reaction of acrylic acid or a derivative thereof with at least one polyalcohol, all of which being interconnected and which supports the inorganic compounds found in said bone structures, makes it possible to reconstruct large areas of bone that have been damaged or have had to be replaced for traumatic or cosmetic reasons.
  • FIG. 3A shows a person 2 with a significant facial deformation, deriving from a lack of chin or mandibular bone structure 5.
  • This area of the maxillofacial structure is difficult to correct due to its complex shape, with concavities, convexities and uneven areas.
  • using a 7 cm wide, 17 cm long and 1 to 3 mm thick roll with a cartilaginous consistency in a composition with Thymus vulgaris extract the surgeon cut and shaped an implant to be applied and managed to correct the defect, as is shown in Fig. 3B.
  • spheres have been implanted in ocular interventions such as enucleation, evisceration and secondary implant.
  • implants or the microporous material 1 for implant according to the invention are used in the reconstruction of the supra- and infra-orbital ridges, vertical laminas, orbital floor, zygomatic arch and malar bones.
  • the microporous material 1 for surgical implant is suitable for use in stomatological injuries; for substitution or replacement in traumatic injuries with bone loss, regardless of the size of bone mass to be replaced or substituted.
  • the microporous material 1 can also be used for tumour lesions, and especially for lesions caused by osteomyelitis.
  • microporous material 1 for surgical implant that is the object of the invention and the implants that can be made from said material, it must mentioned that they provide numerous important advantages and solutions compared to the implants and materials of the prior art, which cannot feasibly be implanted in septic tissue, e.g. with endophthalmitis; they do not allow medicinal products and antibiotics to enter their infrastructure; their molecular structure does no contain bactericidal, anti-microbial and anti- infectious elements; they cannot reconstruct extensive portions of flat bones with dimensions of e.g. 2 to 225 cm 2 ; and they need to be sterilised prior to surgery.
  • the microporous material 1 for surgical implant that is the object of the invention may be individually adapted to each patient by e.g. taking an imprint of said patient's defect on a mask.
  • the surgeon can therefore modify the material 1 during surgery by cutting with a scalpel or scissors as has been described above.
  • all that is needed is to adapt it by cutting a portion from the available material 1 and adding it to the surface where it is needed, securing it with a catgut suture.
  • the material 1 can be secured to the tissue with a conventional surgical suture.
  • the use of the material 1 makes it possible to reduce the time and complexity of preparing surgical interventions, as no prior sterilisation is needed because the liquid in which it is fully or partially submerged provides it with sterilisation. Moreover, while it is submerged in the composition with an ester type compound, its properties remain uncontaminated. In this composition with carvacrol, the microporous material 1 can be kept for long periods of time (if it has not been contaminated) without any changes to its properties or its molecular structure.
  • the material 1 hardens due to a natural endothermic chemical reaction without the need for catalysts or plasticisers.
  • the dynamics of its behaviour are due to the fact that its molecular structure covers a surface area of 3500 cm 2 for absorptive interaction on the molecule-cell exchange wall.
  • the specific weight of the microporous material 1 for surgical implant is less than that of water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une substance microporeuse (1) pour implant chirurgical qui comprend des composés inorganiques se trouvant dans les structures osseuses, en particulier du phosphate de calcium et des sels minéraux, caractérisée en ce qu'elle possède une consistance cartilagineuse en présence d'une composition comprenant un composé de type ester; et en ce qu'elle comprend une matrice qui supporte des composés inorganiques se trouvant dans lesdites structures osseuses. La substance (1) peut être obtenue par traitement d'un constituant solide extrait de fossiles marins et son mélange à une matrice liquide de constituants interconnectés.
PCT/EP2007/006093 2007-07-10 2007-07-10 Substance microporeuse pour implant chirurgical WO2009006921A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/006093 WO2009006921A1 (fr) 2007-07-10 2007-07-10 Substance microporeuse pour implant chirurgical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/006093 WO2009006921A1 (fr) 2007-07-10 2007-07-10 Substance microporeuse pour implant chirurgical

Publications (1)

Publication Number Publication Date
WO2009006921A1 true WO2009006921A1 (fr) 2009-01-15

Family

ID=38895886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/006093 WO2009006921A1 (fr) 2007-07-10 2007-07-10 Substance microporeuse pour implant chirurgical

Country Status (1)

Country Link
WO (1) WO2009006921A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093576A (en) * 1975-04-18 1978-06-06 Sulzer Brothers, Ltd. Mixture for anchoring bone implants
WO1989006944A1 (fr) * 1988-01-26 1989-08-10 Thierry Rainier Besins Systeme de formation de depots subperiostaux pour restauration faciale
US5618549A (en) * 1993-05-13 1997-04-08 Inoteb Use of particles of a biocompatible and bioabsorbable calcium salt as active ingredient in the preparation of a medicinal product intended for the local treatment of bone demineralization diseases
WO2000047214A1 (fr) * 1999-02-09 2000-08-17 Sloan-Kettering Institute For Cancer Research Ciments osseux anti-resorption et implants osseux allogenes, autogreffes et xenogreffes
WO2004071543A1 (fr) * 2003-02-13 2004-08-26 Synthes Ag Chur Melange injectable de remplacement d'os
US20040253278A1 (en) * 2002-08-27 2004-12-16 James Maxwell Breath Freshening and Oral Cleansing Product Using Carvacrol
WO2006045851A1 (fr) * 2004-10-04 2006-05-04 Jose Bouza Barrera Materiau chirurgical a influence inductive, conductive et d'osteointegration

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093576A (en) * 1975-04-18 1978-06-06 Sulzer Brothers, Ltd. Mixture for anchoring bone implants
WO1989006944A1 (fr) * 1988-01-26 1989-08-10 Thierry Rainier Besins Systeme de formation de depots subperiostaux pour restauration faciale
US5618549A (en) * 1993-05-13 1997-04-08 Inoteb Use of particles of a biocompatible and bioabsorbable calcium salt as active ingredient in the preparation of a medicinal product intended for the local treatment of bone demineralization diseases
WO2000047214A1 (fr) * 1999-02-09 2000-08-17 Sloan-Kettering Institute For Cancer Research Ciments osseux anti-resorption et implants osseux allogenes, autogreffes et xenogreffes
US20040253278A1 (en) * 2002-08-27 2004-12-16 James Maxwell Breath Freshening and Oral Cleansing Product Using Carvacrol
WO2004071543A1 (fr) * 2003-02-13 2004-08-26 Synthes Ag Chur Melange injectable de remplacement d'os
WO2006045851A1 (fr) * 2004-10-04 2006-05-04 Jose Bouza Barrera Materiau chirurgical a influence inductive, conductive et d'osteointegration

Similar Documents

Publication Publication Date Title
Baino et al. Bioceramics in ophthalmology
Saijo et al. Maxillofacial reconstruction using custom-made artificial bones fabricated by inkjet printing technology
EP2252338B1 (fr) Matériau de greffe osseuse et ses utilisations
DE69729647T2 (de) Verfahren zur Herstellung von wenigkristallinem Calciumphosphat und Verfahren zu dessen Verwendung
CN105013006A (zh) 一种生物可吸收骨修复材料及其应用与制作方法
KR20060003852A (ko) 매크로다공성 합성 수지 및 생활성 유리 입자로부터제조된 복합 외과적 이식물
Shi et al. Customized barrier membrane (titanium alloy, poly ether-ether ketone and Unsintered hydroxyapatite/poly-l-Lactide) for guided bone regeneration
TW201215369A (en) Spinal implant structure and method for manufacturing the same
WO2014079178A1 (fr) Prothèse de mâchoire
RU2218895C1 (ru) Способ контурной пластики, восстановления, коррекции, устранения или замещения дефектов, повреждений или деформаций костной или хрящевой ткани и имплантат для его реализации
CN111759544B (zh) 一种口腔骨再生修复系统及其制备方法
RU195801U1 (ru) Каркас индивидуальный для исправления дефектов мозгового и лицевого отделов скелета головы
RU28608U1 (ru) Эндопротез из керамического материала
RU2182817C1 (ru) Внутрикостный корневой остеокондуктивный дентальный имплантат и материал для его изготовления
CN203802555U (zh) 一种颈椎前路内固定系统
WO2009006921A1 (fr) Substance microporeuse pour implant chirurgical
RU25996U1 (ru) Имплантат для контурной пластики, восстановления, коррекции, устранения или замещения дефектов, повреждений или деформаций костной или хрящевой ткани
Xu et al. Reconstruction of craniomaxillofacial bone defects with customized prosthesis of hydroxyapatite/epoxide acrylate maleic compound designed by computer-aided technique
Onwubu et al. Hydrocolloids in Dentistry
DE19945529A1 (de) Implantat zur funktionserhaltenden Rekonstruktion von Skelettdefekten und Verfahren für die Herstellung
KR102069847B1 (ko) 3d 프린팅에 의한 골 이식재의 제조방법
CN106344214A (zh) 采用动物骨骼去有机化3d打印制备可植入骨移植物的方法
CN112842623A (zh) 一种羟基磷灰石表面修饰3d生物打印可降解人工肋骨的方法
CN115804673B (zh) 一种定制化的颌面修复体及其制备方法
RU196140U1 (ru) Имплантат индивидуальный для замещения дефектов зубных рядов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765152

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.03.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 07765152

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载